IRAK1 and systemic lupus erythematosus: Among them, Edecesertib (GS-5718; IRAK4i) [64,65], Zimlovisertib (PF-06650833; IRAK4i) [66,67,68], and R835 (IRAK1/4i) [69,70,71] have shown promising effectiveness in murine models of lupus, ex vivo proof-of-mechanism in human PBMCs, and favorable safety in phase I studies.